Clinical Trials Logo

Filter by:
NCT ID: NCT06369441 Not yet recruiting - Cancer Clinical Trials

Collection of Biological Specimens and Associated Health Information

Start date: April 2024
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to collect blood samples from a large number of individuals with cancer to create a database for researchers to use in future studies. Researchers may use this database to discover new ways to detect and treat cancer and other diseases. Future studies may use stored blood samples to discover how genes affect health and disease.

NCT ID: NCT06369298 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Study of JK07 in Patients With Chronic Heart Failure

RENEU-HF
Start date: March 28, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) > 40% and ≤ 65%. Participants in both cohorts will be randomized into either low dose JK07, high dose JK07 or placebo. Participants will have a 2:1 chance of receiving JK07 versus placebo.

NCT ID: NCT06369285 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

ALISCA-Breast1
Start date: December 31, 2024
Phase: Phase 2
Study type: Interventional

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy.

NCT ID: NCT06369272 Completed - Pregnancy Clinical Trials

Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy

Start date: March 1, 2023
Phase:
Study type: Observational

The primary objectives of this study are: In infants of women exposed to SPIKEVAX during pregnancy, to assess: - If exposure to SPIKEVAX during pregnancy is associated with an increased birth prevalence of major congenital malformations (MCMs). - If exposure to SPIKEVAX during pregnancy is associated with an increased birth prevalence of adverse neonatal and infant outcomes, specifically neonatal encephalopathy, small for gestational age, respiratory distress in the newborn, and incidence of hospitalization due to infections including coronavirus disease 2019 (COVID-19). - In women exposed to SPIKEVAX during pregnancy, to assess whether exposure to SPIKEVAX is associated with an increased prevalence of hypertensive disorders [e.g., pre-eclampsia, eclampsia, and gestational hypertension] gestational diabetes, and post-partum hemorrhage; and - To assess whether exposure to SPIKEVAX during pregnancy is associated with an increased incidence of stillbirth, preterm birth, and medically attended spontaneous abortion.

NCT ID: NCT06369259 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Start date: October 31, 2024
Phase: Phase 2
Study type: Interventional

To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.

NCT ID: NCT06369246 Not yet recruiting - Clinical trials for Advanced Prostate Cancer

PRORAD-5 PROstate RADiation in 5 Fractions: Phase Ib Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer

Start date: October 31, 2024
Phase: Phase 2
Study type: Interventional

To look at the safety and effectiveness of stereotactic body radiation therapy (SBRT) in treating advanced or high-risk prostate cancer.

NCT ID: NCT06369155 Not yet recruiting - Uterine Cancer Clinical Trials

Azenosertib in Uterine Serous Carcinoma: Biomarker Study

Start date: September 2024
Phase: Phase 2
Study type: Interventional

This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)

NCT ID: NCT06369077 Recruiting - Clinical trials for Glaucoma, Open-Angle

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

Start date: April 2024
Phase: Phase 4
Study type: Interventional

IOP effect of half-dose latanoprost dorzolamide-timolol will be compared to full dose. Further comparison will be made timolol-brimonidine-dorzolamide-bimatoprost. Dry eye effects of the different treatments will be assessed.

NCT ID: NCT06368986 Recruiting - HIV Infections Clinical Trials

A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants

Start date: April 17, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate effect of food (in fasted and fed conditions) on the bioavailability of CAI VH4011499.

NCT ID: NCT06368830 Recruiting - Clinical trials for Oropharyngeal Dysphagia

Oral and Swallowing Function in Older Adults

Start date: June 3, 2024
Phase:
Study type: Observational

The purpose of this study is to learn about oral and swallowing function in older adults presenting to the emergency department. The hypothesis is that older adults often have problems with oral and swallowing function and these problems relate to other conditions. Study activities are done during the emergency department visit and include providing saliva samples, completing a bedside water swallow test, completing oral function assessments, completing respiratory function tests, and answering survey questions.